Currently, Pacific Biosciences of California Inc [PACB] is trading at $1.88, down -2.59%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PACB shares have lost -13.36% over the last week, with a monthly amount glided 13.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pacific Biosciences of California Inc [NASDAQ: PACB] stock has seen the most recent analyst activity on November 11, 2024, when UBS downgraded its rating to a Neutral. On April 22, 2024, downgrade downgraded it’s rating to Neutral. Goldman downgraded its rating to a Neutral and decreased its price target to $2.50 on April 18, 2024. Stephens initiated its recommendation with a Overweight and recommended $11 as its price target on December 14, 2023. In a note dated December 13, 2023, Wolfe Research initiated an Peer Perform rating.
This stock has fluctuated between a low of $0.85 and a high of $2.72 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $1.6 within the next 12 months. Pacific Biosciences of California Inc [NASDAQ: PACB] shares were valued at $1.88 at the most recent close of the market. An investor can expect a potential drop of -14.89% based on the average PACB price forecast.
Analyzing the PACB fundamentals
Trailing Twelve Months sales for Pacific Biosciences of California Inc [NASDAQ:PACB] were 154.58M which represents -3.82% decline. Gross Profit Margin for this corporation currently stands at -2.09% with Operating Profit Margin at -4.13%, Pretax Profit Margin comes in at -3.26%, and Net Profit Margin reading is -3.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -2.9 and Total Capital is -0.86. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of19.4.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.8100 points at the first support level, and at 1.7400 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.0000, and for the 2nd resistance point, it is at 2.1200.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Pacific Biosciences of California Inc [NASDAQ:PACB] is 6.24. As well, the Quick Ratio is 5.40, while the Cash Ratio is 0.89. Considering the valuation of this stock, the price to sales ratio is 3.67, the price to book ratio is 15.72.
Transactions by insiders
Recent insider trading involved Van Oene Mark, See Remarks, that happened on Aug 18 ’25 when 26836.0 shares were sold. Officer, MARK VAN OENE completed a deal on Aug 18 ’25 to buy 26836.0 shares. Meanwhile, See Remarks Farmer Michele sold 5195.0 shares on May 19 ’25.
